

## **PROFESSOR SCOTT DAVID SOLOMON**

I have the great pleasure to introduce **Professor Scott David Solomon**, who was nominated for the Doctor Honoris Causa title by Rector Béla Merkely. Scott D. Solomon, MD is The Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School and Senior Physician at Brigham and Women's Hospital. He received his Bachelor degree from Williams College and his medical degree from Harvard Medical School.

Dr. Solomon's research interests have focused on changes in ventricular structure and function following myocardial injury, modifiers of risk and influences of outcome in patients following myocardial infarction and with chronic heart failure, cardiovascular safety of non-cardiovascular therapies, factors that influence the transition from hypertension to heart failure, and heart failure with preserved ejection fraction. He has pioneered the use of cardiac imaging in cardiovascular drug and device development and use of imaging in clinical trials. He and his research group have played a leading role in many international clinical trials in heart failure, hypertension and myocardial infarction, including the SAVE, HEART, VALIANT, CHARM, PEACE, OVERTURE, MADITCRT, ALOFT, ALLAY, TREAT, RED-HF, ALTITUDE, FREEDOM, TOPCAT trials. He led the NIH-sponsored Celecoxib Cross-trials Safety Study which directly informed regulatory agencies about the safety of widely used non-steroidal anti-inflammatory agents. He directs the Cardiac Imaging Core Laboratory and the Clinical Trials Endpoints Center at Brigham and Women's Hospital. He directs the Cardiac Imaging Center for the NHLBI Atherosclerosis Risk in Communities (ARIC) study and Hispanic Community Health Study – Study of Latinos (HCHS-SOL), the two largest NIH cohort studies. Dr. Solomon has recently studied the role for angiotensin receptor neprilysin inhibition in heart failure, serving as executive committee member for the PARADIGM-HF trial. He led the first successful Phase II trial in heart failure with preserved ejection fraction and is currently leading the ongoing PARAGON-HF outcomes trial in HFpEF. He is PI for the NHLBI funded INVESTED trial studying influenza vaccine to reduce cardiovascular events.

Dr. Solomon leads a research group consisting of 10 faculty members, 8 research fellows and 40 support staff. He receives extensive research support from the NIH and multiple industry sponsors. He has directed the Harvard Medical School Cardiovascular Clerkship and the Echocardiography training program at Brigham and Women's Hospital. He has authored more than 500 peer-reviewed articles, reviews and editorials, three textbooks of cardiac imaging, including Essential Echocardiography, A Companion to Braunwald's Heart Disease (2018), and the Echocardiography sections for the 10th and 11th edition of Braunwald's Heart Disease and 19th and 20th edition Harrison's Principles of Internal Medicine. He is listed by Thomson-Reuters as one of the most highly cited scientists in the past 10 years. He has served as Cardiology Section Editor at UpToDate, Associate Editor at Circulation, and is currently International Associate Editor at the European Heart Journal.

The collaboration between Professor Solomon and Semmelweis University Heart and Vascular Center has been ongoing for more than a decade. During this time, 14 joint publications have been born about the pharmacological and non-pharmacological treatment of Heart Failure in such journals as the New England Journal of Medicine, the Circulation and the Journal of American College of Cardiology. In addition, Professor Solomon involved Semmelweis University Heart and Vascular Center in three of his milestone trials: MADIT-CRT, PARADIGMA and PARAGON. In PARAGON trial which examines Diastolic Heart

Failure, Semmelweis University Heart and Vascular Center randomized the most patients on a world level.